Being BRCA1 positive means a genetic test has found a harmful change (mutation) in your BRCA1 gene, which significantly raises your lifetime risk of developing certain cancers, most notably breast and ovarian cancer. About 55% to 72% of women with a BRCA1 mutation will develop breast cancer by age 80, compared to roughly 13% of women in the general population. It does not mean you have cancer now or that cancer is inevitable, but it does mean your body has lost one layer of a critical defense system.
What the BRCA1 Gene Normally Does
Every cell in your body sustains DNA damage on a regular basis. Most of the time, specialized proteins detect and fix these breaks before they cause problems. The BRCA1 protein is one of the most important players in this repair system, particularly for double-strand breaks, the most dangerous type of DNA damage where both sides of the DNA ladder snap at once.
BRCA1 helps coordinate a high-fidelity repair process called homologous recombination, which uses the matching chromosome as a template to stitch the break back together accurately. When BRCA1 is working properly, it protects your genome’s integrity. When one copy of the gene carries a harmful mutation, your cells still have a backup copy from the other parent. But if that second copy is lost or damaged over time in a particular cell, the cell can no longer perform accurate repairs. It falls back on sloppier, error-prone methods, and genetic mistakes accumulate. That accumulation is what drives cells toward becoming cancerous.
How You Inherit a BRCA1 Mutation
BRCA1 mutations follow an autosomal dominant inheritance pattern. You have two copies of every gene, one from each parent. If one parent carries a BRCA1 mutation, each of their children has a 50% chance of inheriting it. Both men and women can carry and pass on the mutation, even if they never develop cancer themselves. A father with a BRCA1 mutation can pass it to his daughter just as easily as a mother can.
Certain populations have higher rates of BRCA1 mutations. People of Ashkenazi Jewish descent carry specific founder mutations at a rate of roughly 1 in 40, compared to about 1 in 300 to 1 in 500 in the general population. Icelandic, Norwegian, and Dutch populations also carry identifiable founder mutations at elevated rates.
Cancer Risks for Women
The most well-known risk is breast cancer. Women with a harmful BRCA1 mutation face a lifetime breast cancer risk of roughly 55% to 72%, and they tend to develop it at younger ages than women without the mutation. BRCA1-related breast cancers are also more likely to be “triple-negative,” a subtype that doesn’t respond to hormone-based therapies and historically has been harder to treat.
Ovarian cancer risk is the other major concern. Women with a BRCA1 mutation have a 39% to 44% lifetime risk of ovarian cancer, compared to about 1.2% in the general population. Ovarian cancer is particularly worrisome because it’s difficult to detect early and is often diagnosed at advanced stages.
BRCA1 carriers also face a modestly elevated risk of pancreatic cancer, with up to 5% developing it over a lifetime versus about 1.7% in the general population.
Cancer Risks for Men
BRCA1 mutations aren’t just a women’s health issue. Men who carry a BRCA1 mutation have an elevated risk of prostate cancer, estimated at 7% to 26% by age 80, compared to about 10.6% in the general population. While the increase sounds modest, BRCA1-associated prostate cancers tend to be more aggressive and diagnosed at more advanced stages.
Male BRCA1 carriers also have a small but real increased risk of breast cancer and pancreatic cancer. Men who test positive typically benefit from earlier and more frequent prostate cancer screening.
What Screening Looks Like
If you’re BRCA1 positive, your screening schedule will be more intensive than standard recommendations. For women, breast cancer surveillance typically starts around age 25, which is about 15 years earlier than guidelines for average-risk women. The routine generally includes a clinical breast exam every six months, a breast MRI once a year starting at 25, and annual mammograms added in later, usually starting around age 30. The MRI and mammogram are often staggered six months apart so that you’re getting some form of imaging every six months.
Ovarian cancer screening is more complicated because no highly reliable early-detection method exists for it. Some providers offer transvaginal ultrasound and blood tests, but these have limited sensitivity. This is one reason why preventive surgery is discussed more aggressively for ovarian cancer risk than for breast cancer risk.
Options for Reducing Risk
Knowing your BRCA1 status gives you options that people without this information don’t have. The most impactful is preventive (prophylactic) surgery. Bilateral mastectomy, the removal of both breasts, reduces breast cancer risk by at least 95% in women with a BRCA1 mutation. Many women choose this route, though it’s a deeply personal decision that involves weighing the physical and emotional impact of surgery against the ongoing anxiety and intensity of surveillance.
Risk-reducing removal of the ovaries and fallopian tubes (salpingo-oophorectomy) is the primary strategy for ovarian cancer prevention because screening for ovarian cancer remains unreliable. This surgery essentially eliminates ovarian cancer risk and may also reduce breast cancer risk, though the evidence on that secondary benefit is mixed. Most guidelines suggest considering this surgery after childbearing is complete, typically between ages 35 and 40 for BRCA1 carriers.
For those who prefer not to pursue surgery, certain medications can lower breast cancer risk. These don’t eliminate the risk entirely but can reduce it meaningfully while you continue with intensive screening.
How BRCA1 Status Affects Cancer Treatment
If you do develop cancer as a BRCA1 carrier, your mutation actually opens up a targeted treatment option. A class of drugs called PARP inhibitors exploits the exact weakness that makes BRCA1-mutated cells vulnerable. These drugs work by creating persistent gaps in tumor-cell DNA. Normal cells can repair these gaps, but BRCA1-mutant cancer cells cannot. The damage accumulates through multiple rounds of cell division until the cancer cells die. PARP inhibitors are now used to treat BRCA-related cancers of the breast, ovaries, prostate, and pancreas, and they’ve meaningfully improved outcomes for many patients.
This is an important shift in how carriers think about their status. A BRCA1 mutation increases cancer risk, but it also makes certain cancers more treatable with precision therapies that specifically target the mutation’s weakness.
What It Means for Your Family
A positive BRCA1 result has implications beyond the person tested. Because of the 50% inheritance pattern, siblings, parents, and children of a carrier may also carry the mutation. Once one person in a family tests positive, other blood relatives can take a much simpler, targeted test that looks only for the specific mutation already identified. This is less expensive and faster than broad genetic panel testing.
The decision to share genetic results with family members can be complicated. Some relatives may not want to know their status. Others may feel strongly that they need the information. Genetic counselors are trained to help navigate these conversations and can provide guidance on how and when to share results, as well as help family members understand what a positive or negative result would mean for them individually.